---
title: Evaluation of 4D Magnetic Resonance Flow Sequence at Hepatic Level
nct_id: NCT02821078
overall_status: COMPLETED
phase: NA
sponsor: Centre Hospitalier Universitaire, Amiens
study_type: INTERVENTIONAL
primary_condition: Magnetic Resonance Imaging
countries: France
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02821078.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02821078"
ct_last_update_post_date: 2025-11-19
last_seen_at: "2026-05-12T06:46:00.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Evaluation of 4D Magnetic Resonance Flow Sequence at Hepatic Level

**NCT ID:** [NCT02821078](https://clinicaltrials.gov/study/NCT02821078)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 44
- **Lead Sponsor:** Centre Hospitalier Universitaire, Amiens
- **Conditions:** Magnetic Resonance Imaging
- **Start Date:** 2017-03-16
- **Completion Date:** 2019-01-24
- **CT.gov Last Update:** 2025-11-19

## Brief Summary

The objective of the project is to establish the 3D velocity mapping of the hepatic vasculature and its consistency

## Detailed Description

The objective of the project is to establish the 3D velocity mapping of the hepatic vasculature and its consistency. Specifically, the investigators will assess the consistency of the quantitative data by measuring hepatic blood Inflow (hepatic artery + portal vein) and outflow (inferior vena cava differential flow). According to the mass conservation physical property, blood inflow must equals blood outflow. The relative gap between the measured values will characterize the consistency of the acquisition.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Participants have fasted for 6 hours before examination
* Adult participants

Exclusion Criteria:

* Anyone with a classic contraindication to MRI
* Recanalized umbilical vein
* Severe obesity
* Gadolinium chelate allergy
```

## Arms

- **Participants** (EXPERIMENTAL) — In addition to the standard clinical MR protocol, 2 added sequences:

* 4D flow imaging sequence
* standard 2D-PhaseContrast at portal trunk level as reference

## Interventions

- **4D flow imaging sequence** (OTHER) — 4D flow imaging sequence

## Primary Outcomes

- **Hepatic blood flow difference** _(time frame: Day 0)_ — difference between (hepatic artery + portal vein flows) and inferior vena cava differential flow (infra and supra hepatic)

## Secondary Outcomes

- **Comparison between 4D and 2D flow** _(time frame: Day 0)_

## Locations (1)

- CHU Amiens, Amiens, France

## Recent Field Changes (last 30 days)

- `design.enrollmentCount` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.chu amiens|amiens||france` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02821078.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02821078*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*